ClinicalTrials.gg
CompletedNCT01432262Updated Jan 25, 2013Results posted

13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

A Phase 3 interventional study of vaccine-13vPnC and vaccine-13vPnC in Pneumococcal Infections, sponsored by Pfizer. Completed at 4 sites in Mexico. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-25.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
23rd of 44
324 · median 328
Started
2011
with 2 others
Phase 3
19 of 44
none open now
Registered
14th of 44
by date
Lead sponsor
16 of 44
Pfizer

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 23rd largest by enrollment, is one of 3 that started in 2011, is one of 19 in phase 3, and was the 14th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.

03

Conditions studied

  • Pneumococcal Infections

Keywords

  • prevention of pneumococcal diseases
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female older than 50 years of age
  • Eligibility must be determined by medical history, physical exam and clinical judgment
  • Able to complete an electronic diary
  • Available for duration of study
  • Negative pregnancy test for subjects in group 2 age 50 to 64 years
  • Practice abstinence or use reliable if age is 50 to 64 years

Exclusion criteria

Exclusion Criteria:

  • History of allergic reaction to any vaccine
  • Previous vaccination with licensed or experimental pneumococcal vaccine
  • S. pneumonia infection within past 5 years before product administration
  • Known or suspected immunodeficiency or received treatment including cytotoxic agents or systemic , serious chronic disorder such as cancer
  • Receipt of plasma products or immunoglobulins within 60 days
  • Bleeding conditions or diathesis
  • Receipt of investigational product within 28 days before study entry
  • Other severe acute or chronic medical or psychiatric condition
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    Group 1

    =\> 65 years of age

    Biological: vaccine-13vPnC

  • Experimental
    Group 2

    50 to 64 years of age

    Biological: vaccine-13vPnC

Interventions

  • Biologicalvaccine-13vPnC

    Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)

    Also known as: 13-valent pneumococcal conjugate vaccine

  • Biologicalvaccine-13vPnC

    Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)

    Also known as: 13-valent pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination

    Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5\*limit of detection (LOD \[8\]) = (titer of 4) for the purpose of calculating the OPA GMT.

    Time frame: One month (28 to 42 days) after vaccination

  2. Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination

    Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters \[cm\]), Moderate (5.1 to 10.0 cm), Severe (\>10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).

    Time frame: Within 14 days after vaccination

  3. Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination

    Systemic events reported using electronic diary. Fever-Any:\>=38 degrees Celsius (C), Mild (M):\>=38 to \<38.5 degrees C, Moderate(Mod):\>=38.5 to \<39 degrees C, Severe (S):\>=39 to \<=40 degrees C, Potentially life threatening:\>40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:\>2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:\>=6/d. All reports of fever \>40 degrees C were confirmed as data entry errors.

    Time frame: Within 14 days after vaccination

  4. Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Baseline up to 1 Month (28 to 42 days) after vaccination

Secondary outcomes

  1. Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination

    Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

    Time frame: One month (28 to 42 days) after vaccination

  2. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination

    Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: Pre-vaccination to 1 month (28 to 42 days) after vaccination

07

Results

Posted Jan 8, 2013

Participant flow

Participant flow — Overall Study
Milestone13vPnC, Cohort 113vPnC, Cohort 2
Started162162
Vaccinated162161
Completed160161
Not completed21
Withdrew: Withdrawal by subject21

Outcome measures

PrimarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination

Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5\*limit of detection (LOD \[8\]) = (titer of 4) for the purpose of calculating the OPA GMT.

Time frame:
One month (28 to 42 days) after vaccination
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination
titer13vPnC, Cohort 113vPnC, Cohort 2
1120 (92.3 to 155.3)84 (62.8 to 112.5)
388 (72.4 to 106.9)89 (70.8 to 111.5)
41729 (1377.6 to 2170.9)1209 (977.1 to 1495.9)
5288 (208.6 to 398.3)285 (208.7 to 388.9)
6A3380 (2732.9 to 4179.6)3343 (2625.2 to 4256.6)
6B3982 (3273.2 to 4845.0)3384 (2708.6 to 4227.2)
7F3130 (2660.9 to 3681.4)1929 (1564.7 to 2378.1)
9V2416 (1901.0 to 3071.4)1402 (1030.8 to 1906.8)
141569 (1267.9 to 1940.3)1316 (1068.9 to 1619.3)
18C3063 (2405.9 to 3900.7)2197 (1727.2 to 2794.8)
19A1542 (1257.9 to 1889.0)1196 (990.6 to 1443.1)
19F1104 (828.1 to 1473.1)1188 (905.0 to 1558.6)
23F879 (650.3 to 1187.7)930 (667.1 to 1296.2)
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination

Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters \[cm\]), Moderate (5.1 to 10.0 cm), Severe (\>10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).

Time frame:
Within 14 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination
percentage of participants13vPnC, Cohort 113vPnC, Cohort 2
Redness: Any (n=125, 120)14.4 (8.8 to 21.8)15.8 (9.8 to 23.6)
Redness: Mild (n=124, 120)9.7 (5.1 to 16.3)13.3 (7.8 to 20.7)
Redness: Moderate (n=125, 115)8.8 (4.5 to 15.2)7.0 (3.1 to 13.2)
Redness: Severe (n=125, 112)2.4 (0.5 to 6.9)0.0 (0.0 to 3.2)
Swelling: Any (n=130, 120)21.5 (14.8 to 29.6)13.3 (7.8 to 20.7)
Swelling: Mild (n=127, 120)18.1 (11.8 to 25.9)11.7 (6.5 to 18.8)
Swelling: Moderate (n=127, 114)8.7 (4.4 to 15.0)4.4 (1.4 to 9.9)
Swelling: Severe (n=125, 113)2.4 (0.5 to 6.9)0.9 (0.0 to 4.8)
Pain at injection site: Any (n=151, 137)75.5 (67.8 to 82.1)60.6 (51.9 to 68.8)
Pain at injection site: Mild (n=151, 136)74.2 (66.4 to 80.9)60.3 (51.6 to 68.6)
Pain at injection site: Moderate (n=130, 117)21.5 (14.8 to 29.6)8.5 (4.2 to 15.2)
Pain at injection site: Severe (n=125, 113)3.2 (0.9 to 8.0)3.5 (1.0 to 8.8)
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination

Systemic events reported using electronic diary. Fever-Any:\>=38 degrees Celsius (C), Mild (M):\>=38 to \<38.5 degrees C, Moderate(Mod):\>=38.5 to \<39 degrees C, Severe (S):\>=39 to \<=40 degrees C, Potentially life threatening:\>40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:\>2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:\>=6/d. All reports of fever \>40 degrees C were confirmed as data entry errors.

Time frame:
Within 14 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination
percentage of participants13vPnC, Cohort 113vPnC, Cohort 2
Fever: Any (n=126, 118)2.4 (0.5 to 6.8)10.2 (5.4 to 17.1)
Fever: Mild (n=126, 113)1.6 (0.2 to 5.6)3.5 (1.0 to 8.8)
Fever: Moderate (n=125, 113)0.8 (0.0 to 4.4)1.8 (0.2 to 6.2)
Fever: Severe (n=124, 113)0.8 (0.0 to 4.4)1.8 (0.2 to 6.2)
Fever: Potentially life threatening (n=124, 116)0.0 (0.0 to 2.9)4.3 (1.4 to 9.8)
Fatigue: Any (n=144, 132)47.2 (38.9 to 55.7)38.6 (30.3 to 47.5)
Fatigue: Mild (n=142, 130)39.4 (31.3 to 48.0)36.2 (27.9 to 45.0)
Fatigue: Moderate (n=134, 125)26.9 (19.6 to 35.2)20.0 (13.4 to 28.1)
Fatigue: Severe (n=126, 113)6.3 (2.8 to 12.1)5.3 (2.0 to 11.2)
Headache: Any (n=140, 129)44.3 (35.9 to 52.9)32.6 (24.6 to 41.4)
Headache: Mild (n=140, 128)39.3 (31.1 to 47.9)30.5 (22.6 to 39.2)
Headache: Moderate (n=129, 119)18.6 (12.3 to 26.4)16.0 (9.9 to 23.8)
Headache: Severe (n=126, 115)4.0 (1.3 to 9.0)5.2 (1.9 to 11.0)
Vomiting: Any (n=125, 113)4.0 (1.3 to 9.1)1.8 (0.2 to 6.2)
Vomiting: Mild (n=125, 113)3.2 (0.9 to 8.0)1.8 (0.2 to 6.2)
Vomiting: Moderate (n=124, 113)1.6 (0.2 to 5.7)0.9 (0.0 to 4.8)
Vomiting: Severe (n=124, 112)0.0 (0.0 to 2.9)0.0 (0.0 to 3.2)
Diarrhea: Any (n=134, 120)26.1 (18.9 to 34.4)15.0 (9.1 to 22.7)
Diarrhea: Mild (n=129, 120)23.3 (16.3 to 31.5)14.2 (8.5 to 21.7)
Diarrhea: Moderate (n=129, 113)6.2 (2.7 to 11.9)1.8 (0.2 to 6.2)
Diarrhea: Severe (n=125, 112)0.8 (0.0 to 4.4)0.9 (0.0 to 4.9)
Muscle pain: Any (n=147, 132)60.5 (52.2 to 68.5)43.9 (35.3 to 52.8)
Muscle pain: Mild (n=146, 129)59.6 (51.2 to 67.6)40.3 (31.8 to 49.3)
Muscle pain: Moderate (n=132, 123)23.5 (16.5 to 31.6)19.5 (12.9 to 27.6)
Muscle pain: Severe (n=125, 116)5.6 (2.3 to 11.2)6.0 (2.5 to 12.0)
Joint pain: Any (n=139, 129)35.3 (27.3 to 43.8)33.3 (25.3 to 42.2)
Joint pain: Mild (n=137, 127)30.7 (23.1 to 39.1)29.9 (22.1 to 38.7)
Joint pain: Moderate (n=130, 123)13.1 (7.8 to 20.1)17.1 (10.9 to 24.9)
Joint pain: Severe (n=125, 116)4.0 (1.3 to 9.1)5.2 (1.9 to 10.9)
Use of medication to treat fever (n=129, 118)11.6 (6.7 to 18.5)13.6 (8.0 to 21.1)
Use of medication to treat pain (n=130, 121)13.8 (8.4 to 21.0)12.4 (7.1 to 19.6)
PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
Baseline up to 1 Month (28 to 42 days) after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
percentage of participants13vPnC, Cohort 113vPnC, Cohort 2
AEs11.1 (6.7 to 17.0)6.2 (3.0 to 11.1)
SAEs0.0 (0.0 to 2.3)1.2 (0.2 to 4.4)
SecondaryPercentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination

Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.

Time frame:
One month (28 to 42 days) after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination
percentage of participants13vPnC, Cohort 113vPnC, Cohort 2
190.3 (84.5 to 94.5)81.0 (74.0 to 86.8)
394.8 (90.0 to 97.7)90.1 (84.2 to 94.4)
497.4 (93.4 to 99.3)98.7 (95.3 to 99.8)
589.2 (83.0 to 93.7)90.8 (85.0 to 94.9)
6A98.7 (95.4 to 99.8)98.1 (94.6 to 99.6)
6B99.4 (96.4 to 100.0)98.7 (95.5 to 99.8)
7F99.4 (96.5 to 100.0)97.5 (93.6 to 99.3)
9V96.8 (92.6 to 98.9)92.3 (86.9 to 95.9)
1498.1 (94.4 to 99.6)98.1 (94.5 to 99.6)
18C98.1 (94.4 to 99.6)98.7 (95.4 to 99.8)
19A99.3 (96.4 to 100.0)99.4 (96.5 to 100.0)
19F95.4 (90.7 to 98.1)96.0 (91.5 to 98.5)
23F94.2 (89.2 to 97.3)91.7 (86.2 to 95.5)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination

Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
Pre-vaccination to 1 month (28 to 42 days) after vaccination
Reported as:
Geometric mean · fold rise
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination
fold rise13vPnC, Cohort 113vPnC, Cohort 2
121.3 (16.17 to 28.16)11.7 (8.70 to 15.82)
312.5 (9.77 to 16.05)7.8 (6.03 to 10.02)
457.7 (36.40 to 91.36)19.9 (13.23 to 29.88)
537.3 (26.06 to 53.47)26.2 (18.74 to 36.72)
6A62.3 (39.00 to 99.36)28.7 (19.76 to 41.70)
6B18.1 (11.61 to 28.15)9.4 (6.61 to 13.45)
7F43.2 (26.94 to 69.17)15.5 (10.05 to 23.80)
9V8.8 (5.72 to 13.43)7.2 (4.72 to 10.98)
145.3 (3.73 to 7.56)3.4 (2.58 to 4.56)
18C44.3 (28.19 to 69.51)13.9 (9.21 to 21.09)
19A30.0 (21.19 to 42.50)11.2 (7.99 to 15.69)
19F42.8 (28.33 to 64.67)20.8 (13.38 to 32.29)
23F63.6 (43.16 to 93.75)35.8 (24.16 to 52.95)

Adverse events

Collected over Adverse events: recorded from signing of informed consent form to 28-42 days post 13vPnC. Participants recorded pre-specified AEs in electronic diary: local reactions and systemic events from Day 1 to 14 post 13vPnC.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC, Cohort 1—0/162 (0%)119/162 (73.5%)
13vPnC, Cohort 2—2/161 (1.2%)88/161 (54.7%)
Most frequent serious events
Most frequent serious events
Event13vPnC, Cohort 113vPnC, Cohort 2
Gastric ulcerGastrointestinal disorders0/1621/161
GastritisGastrointestinal disorders0/1621/161
Benign prostatic hyperplasiaReproductive system and breast disorders0/1621/161
Most frequent other events
Showing 10 of 67
Most frequent other events
Event13vPnC, Cohort 113vPnC, Cohort 2
Pain at injection site AnySkin and subcutaneous tissue disorders114/15183/137
Pain at injection site MildSkin and subcutaneous tissue disorders112/15182/136
Muscle pain AnyGeneral disorders89/14758/132
Muscle pain MildGeneral disorders87/14652/129
Fatigue AnyGeneral disorders68/14451/132
Headache AnyGeneral disorders62/14042/129
Fatigue MildGeneral disorders56/14247/130
Headache MildGeneral disorders55/14039/129
Joint pain AnyGeneral disorders49/13943/129
Joint pain MildGeneral disorders42/13738/127

Baseline characteristics

Age Continuous
Age Continuous(years)13vPnC, Cohort 113vPnC, Cohort 2Total
Mean55.7 ± 4.073.4 ± 5.864.5 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC, Cohort 113vPnC, Cohort 2Total
Female9684180
Male6677143
08

Study locations

4 sites
  • Instituto Mexicano de Investigación Clínica, S.A. de C.V
    Mexico, D.f. 06700, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico, DF 14000, Mexico
  • Star Medica
    Morelia, Michoacan CP 58070, Mexico
  • Hospital General de Durango
    Durango, 34000, Mexico
09

References and documents

Publications

  • Tinoco JC, Juergens C, Ruiz Palacios GM, Vazquez-Narvaez J, Enkerlin-Pauwells HL, Sundaraiyer V, Pathirana S, Kalinina E, Gruber WC, Scott DA, Schmoele-Thoma B. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults >/= 50 years of age in Mexico. Clin Vaccine Immunol. 2015 Feb;22(2):185-92. doi: 10.1128/CVI.00711-14. Epub 2014 Dec 10. PubMed 25499011 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2011
First posted
Sep 12, 2011
Start
Jul 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Results first posted
Jan 8, 2013
Last update
Jan 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01432262
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
Jul 2011
Primary completion
Dec 2011
Completion
Dec 2011
Results posted
Jan 8, 2013
Last update
Jan 25, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion